CEREVEL THERAPEUTICS
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder.
CEREVEL THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2018-10-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.cerevel.com
Total Employee:
251+
Status:
Active
Total Funding:
1.45 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Font Awesome Domain Not Resolving Nginx
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Delix Therapeutics
Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
IMPACT Therapeutics
IMPACT Therapeutics is a China based Company.
Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Trilogy Therapeutics
Trilogy Therapeutics is a Biopharmaceutical company
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
Zomedica
Zomedica is a veterinary pharmaceutical company.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Tony Coles CEO & Chairperson of the Board of Directors @ Cerevel Therapeutics
CEO & Chairperson of the Board of Directors
Kathleen Tregoning Chief Corporate Affairs Officer @ Cerevel Therapeutics
Chief Corporate Affairs Officer
2020-07-01
Raymond Sanchez CMO @ Cerevel Therapeutics
CMO
2019-01-01
John Renger CSO @ Cerevel Therapeutics
CSO
2019-05-01
Kathy Yi CFO @ Cerevel Therapeutics
CFO
2019-06-01
Orly Mishan CBO @ Cerevel Therapeutics
CBO
Ken DiPietro CHRO @ Cerevel Therapeutics
CHRO
Bryan K. Phillips Chief Legal Officer @ Cerevel Therapeutics
Chief Legal Officer
Scott M. Akamine Chief Legal Officer & Corporate Secretary @ Cerevel Therapeutics
Chief Legal Officer & Corporate Secretary
2021-05-01
Mark Bodenrader Interim Chief Financial Officer @ Cerevel Therapeutics
Interim Chief Financial Officer
Founder
Stock Details
Investors List
Novaquest Capital Management
Novaquest Capital Management investment in Post-IPO Equity - Cerevel Therapeutics
Bain Capital
Bain Capital investment in Post-IPO Equity - Cerevel Therapeutics
T. Rowe Price
T. Rowe Price investment in Post-IPO Equity - Cerevel Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Cerevel Therapeutics
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Cerevel Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Cerevel Therapeutics
Adage Capital Management
Adage Capital Management investment in Post-IPO Equity - Cerevel Therapeutics
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Cerevel Therapeutics
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Cerevel Therapeutics
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - Cerevel Therapeutics
Key Employee Changes
Official Site Inspections
http://www.cerevel.com Semrush global rank: 2.62 M Semrush visits lastest month: 6.61 K
- Host name: 159.180.132.176
- IP address: 159.180.132.176
- Location: North Chicago United States
- Latitude: 42.325
- Longitude: -87.8561
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60064
More informations about "Cerevel Therapeutics"
Cerevel is now part of AbbVie | AbbVie - Cerevel …
Cerevel is now part of AbbVie. Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders. Read the announcement. Neuroscience.See details»
Cerevel Therapeutics - Wikipedia
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease. Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types. The company has stated its approach to neurotherapy development can be viewed as: • Development of treatment opportunities by precisely identifying and targeting the neurocircuitry t…See details»
AbbVie to Acquire Cerevel Therapeutics in Transformative …
Dec 6, 2023 Information regarding Cerevel's directors and executive officers is set forth in Cerevel's proxy statement on Schedule 14A for its 2023 Annual Meeting of Stockholders, …See details»
AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel's common stock will cease to trade on the NASDAQ stock exchange …See details»
Cerevel Therapeutics - Crunchbase Company Profile
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with …See details»
AbbVie Completes Acquisition of Cerevel Therapeutics - Yahoo …
Aug 1, 2024 Cerevel's pipeline is highly complementary to AbbVie's existing neuroscience portfolio and the completion of the acquisition is an important step forward to delivering new …See details»
Cerevel Therapeutics Acquisition: Key Details, Impact, and What …
Cerevel is now fully integrated into AbbVie's operations, with its team welcomed into the larger organization. This integration leverages AbbVie's commercial capabilities, international …See details»
Cerevel Therapeutics Debuts as Publicly Traded Neuroscience …
Oct 27, 2020 Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated …See details»
AbbVie Completes Acquisition of Cerevel Therapeutics
Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms …See details»
Cerevel Therapeutics - Contacts, Employees, Board Members, …
Organization. Cerevel Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 10. Number of …See details»
Cerevel Therapeutics - Funding, Financials, Valuation
Cerevel Therapeutics is a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric disorders. New. Resources. Advanced Search. ... How much funding has this organization raised over time? Show . …See details»
EX-99.1 - SEC.gov
Aug 1, 2024 AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel’s common stock will cease to trade on the NASDAQ stock exchange …See details»
Cerevel Therapeutics LLC - Drug pipelines, Patents, Clinical
Explore Cerevel Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 40 clinical trials, 87 news, and 1 literature, Disease Domain:Nervous System Diseases, …See details»
AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel’s common stock will cease to trade on the NASDAQ stock exchange …See details»
Mission, Vision & Core Values of Cerevel Therapeutics
Dec 19, 2024 At Cerevel Therapeutics, our mission is to improve the lives of patients suffering from neurological and neuropsychiatric disorders by developing innovative and effective …See details»
AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer
Dec 7, 2023 Cerevel’s clinical pipeline also includes darigabat, an α2/3/5-selective GABAA receptor PAM currently under in a phase 2a proof-of-concept trial in epilepsy and panic …See details»
Cerevel Company Profile - Office Locations, Competitors ... - Craft
Aug 1, 2024 Cerevel Therapeutics is a biopharmaceutical company focused on developing therapies to treat disorders of the central nervous system (CNS). The company has a portfolio …See details»
Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS …
Oct 23, 2018 About Cerevel Therapeutics Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous …See details»
Cerevel to raise $445M, hit Wall Street via blank check company
Jul 31, 2020 RELATED: Pfizer CNS spinout Cerevel brings on new CMO to launch phase 3 work in Parkinson’s disease The cash will push a trio of assets through the clinic, including …See details»
Entromy partners with Cerevel as the exponentially-growing firm ...
Cerevel was founded to pursue a dedicated mission to relentlessly find paths to change the course of disease for people living with a broad range of neurological and neuropsychiatric …See details»